Randomized comparison of @entity5646 and XXXX in gram-negative upper @entity293 .

@entity1 @entity3551 @entity2261 @entity293 @entity1011 @entity582 @entity5646
In order to evaluate the efficacy and safety of @entity5646 in hospitalized @entity1 with upper @entity293 ( @entity293 ), a comparative clinical study with @entity2261 was performed. 62/60% ( @entity5646 / @entity2261 ) of the @entity1 had a complicating factor, @entity3551 . I.v. bolus injections were used at a dose of 1 g @entity5646 or 1.5 g @entity2261 t.i.d., for a mean of 8.2 days (range: five to 14 days) except in @entity1 with @entity582 , who received a mean of 10.3 days (range: seven to 13 days) of therapy. 89% of the @entity1 treated with @entity5646 and 87% of those who received @entity2261 showed clinical cure and the bacteriological cure rate at one week post-therapy was 70% and 73% in the respective groups. The relapse/reinfection rate was high with both drugs; bacteriological cure at one month post-therapy was only 43% after @entity5646 and 40% after @entity2261 . This suggests that these infections may need longer treatment times. Superinfections, mostly asymptomatic urinary colonization, occurred in 7% and 3%, respectively, and adverse reactions in 23% and 12%, respectively, of the @entity1 treated with @entity5646 or @entity2261 , the majority being mild and reversible and only 3% and 3%, respectively, requiring discontinuation of the therapy. The t 1/2 for @entity5646 following a 1 g i.v. bolus was 2.0 h in six @entity1 with creatinine clearance above 80 ml/min and 3.0 h in seven @entity1 with @entity1011 clearance between 35-75 ml/min.
